Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?

The Pharmacogenomics Journal
Catherine J E IngramDallas M Swallow

Abstract

Inter-individual variation of drug metabolising enzymes (DMEs) leads to variable efficacy of many drugs and even adverse drug responses. Consequently, it would be desirable to test variants of many DMEs before drug treatment. Inter-ethnic differences in frequency mean that the choice of SNPs to test may vary across population groups. Here we examine the utility of testing representative groups as a way of assessing what variants might be tested. We show that publicly available population information is potentially useful for determining loci for pre-treatment genetic testing, and for determining the most prevalent risk haplotypes in defined groups. However, we also show that the NHS England classifications have limitations for grouping for these purposes, in particular for people of African descent. We conclude: (1) genotyping of hospital patients and people from the hospital catchment area confers no advantage over using samples from appropriate existing ethnic group collections or publicly available data, (2) given the current NHS England Black African grouping, a decision as to whether to test, would have to apply to all patients of recent Black African ancestry to cover reported risk alleles and (3) the current scarcity of ...Continue Reading

References

Feb 22, 1994·Biochemistry·J A GoldsteinB I Ghanayem
May 26, 1999·Clinical Pharmacology and Therapeutics·T FurutaT Ishizaki
Jul 21, 1999·Epilepsy Research·A E RettieR H Levy
Oct 31, 2001·Nature Genetics·J F WilsonD B Goldstein
Mar 21, 2003·The New England Journal of Medicine·Esteban González BurchardNeil Risch
Apr 17, 2003·European Journal of Clinical Pharmacology·Craig R LeeJoyce A Goldstein
Oct 24, 2003·American Journal of Human Genetics·Matthew Stephens, Peter Donnelly
Nov 18, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Ulrich M ZangerMichel Eichelbaum
Sep 28, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vandana N HiraniJerome M Lasker
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Jamila A PeriniGuilherme Suarez-Kurtz
Oct 6, 2005·The Annals of Pharmacotherapy·Linda A Browning, James A Kruse
Dec 13, 2005·Clinical Pharmacology and Therapeutics·Shinichi InomataHidenori Toyooka
Sep 5, 2006·Annual Review of Genomics and Human Genetics·Richard M Weinshilboum, Liewei Wang
Dec 23, 2006·Pharmacogenomics·Federico Innocenti, Mark J Ratain
Nov 24, 2007·Pharmacogenomics·David Gurwitz, Arno G Motulsky
Jan 15, 2008·Pharmacogenetics and Genomics·Christine LonjouUNKNOWN RegiSCAR study group
Jul 3, 2008·Annual Review of Genomics and Human Genetics·Michael C Campbell, Sarah A Tishkoff
Aug 14, 2008·Clinical Pharmacokinetics·Simone StehleUwe Fuhr
Oct 25, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Asvi A FrancoisElizabeth A Shephard
Feb 12, 2011·Annals of Human Genetics·Laura J HorsfallDallas M Swallow
Aug 16, 2012·European Journal of Human Genetics : EJHG·Naser Ansari PourNeil Bradman
May 24, 2013·Clinical Pharmacology and Therapeutics·S A ScottUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Apr 17, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elaine TsengR Scott Obach
Jun 4, 2014·Pharmacogenetics and Genomics·Ellen M McDonaghTeri E Klein
Jun 11, 2014·Pharmacogenetics and Genomics·Ellen M McDonaghTeri E Klein
Oct 6, 2014·Trends in Cardiovascular Medicine·Julie A Johnson, Larisa H Cavallari
Dec 4, 2014·Nature·Deepti GurdasaniManjinder S Sandhu
Feb 28, 2015·GigaScience·Christopher C ChangJames J Lee
Sep 30, 2015·Clinical Pharmacology and Therapeutics·R S GammalUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Oct 4, 2015·Nature·UNKNOWN 1000 Genomes Project ConsortiumGonçalo R Abecasis
Sep 30, 2016·Expert Opinion on Drug Metabolism & Toxicology·Ian R Phillips, Elizabeth A Shephard
Dec 17, 2016·Pharmacogenetics and Genomics·Daniel H HovelsonMatthew R Nelson
May 10, 2018·Human Molecular Genetics·Ananyo ChoudhuryMichèle Ramsay

❮ Previous
Next ❯

Citations

Feb 7, 2021·Human Molecular Genetics·Garrett HellenthalSam Morris

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
PCR

Software Mentioned

PLINK
mind
PHASE
R environment

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.